A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Trial ID #	NCT01462890; AGO-OVAR17
Phase	III
Drug Class	Angiogenesis Inhibitors: VEGF
Drug Name	Bevacizumab
Alternate Drug Names	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin
Drugs in Trial	Bevacizumab, Carboplatin, Paclitaxel
Eligible Participant	Newly diagnosed stage IIb-IV ovarian cancer
Patients Enrolled	927
Therapy Setting	First-line
Study Design	Open-Label, Randomized
Endpoints	PFS, OS, evaluated per RECIST
Efficacy	CarboPt+Pac+Bev (15 months, n=464) vs CarboPt+Pac+Bev (30 months, n=463): PFS: 24.2 vs 26.0 months, HR: 0.99 (0.85-1.15, p=0.90) OS: 54.3 vs 60.0 months, HR: 1.04 (0.87-1.23, p=0.68)
Clinically Significant Adverse Events	Serious AE: overall (11 vs 14%) Grade 3-4 AE:
Conclusion	Longer treatment with bevacizumab for up to 30 months improves neither PFS nor OS in patients with newly diagnosed ovarian cancer. Therefore bevacizumab treatment duration of 15 months remains standard of care
Reference	Pfisterer J et al. Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial. J Clin Oncol (2023) 41(4):893-902 https://pubmed.ncbi.nlm.nih.gov/36332161/